home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

192.95 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

59 60 Next >

Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints ↗

July 24, 2024

Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps.

Via Benzinga

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails ↗

July 24, 2024

The companies are no longer developing their drug for essential tremor treatment.

Via Investor's Business Daily

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

July 24, 2024

From Sage Therapeutics, Inc.

Via Business Wire

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗

July 22, 2024

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...

Via Benzinga

Key Takeaways From Biogen Analyst Ratings ↗

July 12, 2024

Via Benzinga

Will BIOGEN INC breakout? ↗

July 11, 2024

Technical Insights for BIOGEN INC (NASDAQ:BIIB): Is a Breakout Imminent?

Via Chartmill

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong ↗

July 22, 2024

Biogen previously decided against opting into Ionis' Angelman program.

Via Investor's Business Daily

BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 22, 2024

From The Schall Law Firm

Via Business Wire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)

July 19, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 19, 2024

From The Schall Law Firm

Via Business Wire

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen

July 18, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗

July 16, 2024

Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.

Via Investor's Business Daily

BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 16, 2024

From Schall Law

Via GlobeNewswire

Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings' ↗

July 15, 2024

Via Benzinga

Topics Bankruptcy

BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER ALERT: Only 7 Days Remain For Investors To Move For Lead Plaintiff in Biogen Inc.

July 15, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗

July 15, 2024

Revenue is climbing at these two drug companies -- and the trend should continue.

Via The Motley Fool

Did Eli Lilly Just Get a Leg Up on Novo Nordisk? ↗

July 13, 2024

Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.

Via The Motley Fool

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen

July 12, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm

July 11, 2024

From Kirby McInerney LLP

Via GlobeNewswire

BIIB Investors Have Opportunity to Join Biogen Inc. Securities Fraud Investigation with the Schall Law Firm

July 11, 2024

From The Schall Law Firm

Via Business Wire

BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 09, 2024

From Schall Law

Via GlobeNewswire

BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline

July 08, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

3 Highly Rated Biotech Stocks for Your July Buy List ↗

July 05, 2024

Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.

Via InvestorPlace

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen

July 04, 2024

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Biogen To Contact Him Directly To Discuss Their Options

From Faruqi & Faruqi LLP

Via GlobeNewswire

Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst ↗

July 03, 2024

The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce...

Via Benzinga

BIIB STOCKHOLDERS: Lead Plaintiff Deadline Approaching in Biogen Inc. Class Action; Contact Robbins LLP

July 02, 2024

From Robbins LLP

Via GlobeNewswire

Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai ↗

July 02, 2024

The company is on deck to rival Biogen and Eisai's Leqembi.

Via Investor's Business Daily

BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 02, 2024

From Schall Law

Via GlobeNewswire

Biogen Completes Acquisition of Human Immunology Biosciences

July 02, 2024

From Biogen Inc.

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm

July 01, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com